Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 275194, 6 pages
http://dx.doi.org/10.1155/2014/275194
Research Article

The Usefulness of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Monitoring Systemic Lupus Erythematosus Disease Activity

1Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400 Serdang, Selangor, Malaysia
2Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia
3Department of Medicine, Hospital Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
4Department of Medicine, Hospital Raja Perempuan Zainab II, 15000 Kota Bharu, Kelantan, Malaysia

Received 30 April 2014; Revised 4 August 2014; Accepted 4 August 2014; Published 29 October 2014

Academic Editor: Hironobu Ihn

Copyright © 2014 Hasni Mahayidin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Ahearn, E. L. Erickson, D. Hawkins, and S. M. Manzi, “Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (SLE) and other autoimmune diseases,” United States Patent Application 20100233752, 2010.
  2. M. M. A. Fernando and D. A. Isenberg, “How to monitor SLE in routine clinical practice,” Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. 524–527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. G. K. W. Lam and M. Petri, “Assessment of systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 23, no. 5, pp. S120–S132, 2005. View at Google Scholar · View at Scopus
  4. J. M. Ahearn, C. C. Liu, A. H. Kao, and S. Manzi, “Biomarkers for systemic lupus erythematosus,” Translational Research, vol. 159, no. 4, pp. 326–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D.-J. Min, S.-J. Kim, S.-H. Park et al., “Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody,” Clinical and Experimental Rheumatology, vol. 20, no. 1, pp. 13–18, 2002. View at Google Scholar · View at Scopus
  6. C. Liu and J. M. Ahearn, “The search for lupus biomarkers,” Best Practice and Research: Clinical Rheumatology, vol. 23, no. 4, pp. 507–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Lawson and S. Wolf, “ICAM-1 signaling in endothelial cells,” Pharmacological Reports, vol. 61, no. 1, pp. 22–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. K. D. Elgert, Immunology Understanding the Immune System, John Wiley & Sons, Hobeken, NJ, USA, 2009.
  9. T. Collins, M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, and T. Maniatis, “Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers,” The FASEB Journal, vol. 9, no. 10, pp. 899–909, 1995. View at Google Scholar · View at Scopus
  10. K. Egerer, E. Feist, U. Rohr, A. Pruss, G. R. Burmester, and T. Dorner, “Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus,” Lupus, vol. 9, no. 8, pp. 614–621, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Elwy, Z. A. Galal, and H. E. Hasan, “Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new,” Eastern Mediterranean Health Journal, vol. 16, no. 8, pp. 893–900, 2010. View at Google Scholar · View at Scopus
  12. P. E. Spronk, H. Bootsma, M. G. Huitema, P. C. Limburg, and C. G. M. Kallenberg, “Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study,” Clinical and Experimental Immunology, vol. 97, no. 3, pp. 439–444, 1994. View at Google Scholar · View at Scopus
  13. H. G. Sieberth, “Detection of circulating adhesion molecules ICAM-1, VCAM-1 and E-Selectin in Wegener's granulomatosis, systemic lupus erythematosus and chronic renal failure,” Clinical Nephrology, vol. 43, no. 5, pp. 288–296, 1995. View at Google Scholar · View at Scopus
  14. S. Pizarro, J. Monárrez Espino, A. Ruiz, L. J. Jara, A. Nava, and C. Riebeling-Navarro, “Soluble vascular cell adhesion molecule-1 indicates SLE disease activity and specific organ involvement.,” Revista Alergia Mexico, vol. 54, no. 6, pp. 189–195, 2007. View at Google Scholar · View at Scopus
  15. E. Potlukova and P. Kralikova, “Complement component C1q and anti-C1q antibodies in theory and in clinical practice,” Scandinavian Journal of Immunology, vol. 67, no. 5, pp. 423–430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Horak, Z. Hermanova, J. Zadrazil et al., “C1q complement component and -antibodies reflect SLE activity and kidney involvement,” Clinical Rheumatology, vol. 25, pp. 532–536, 2006. View at Google Scholar
  17. M. Trendelenburg, M. Lopez-Trascasa, E. Potlukova et al., “High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis,” Nephrology Dialysis Transplantation, vol. 21, no. 11, pp. 3115–3121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Tsirogianni, E. Pipi, and K. Soufleros, “Relevance of anti-C1q autoantibodies to lupus nephritis,” Annals of the New York Academy of Sciences, vol. 1173, pp. 243–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Katsumata, K. Miyake, Y. Kawaguchi et al., “Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients,” Arthritis and Rheumatism, vol. 63, no. 8, pp. 2436–2444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Zhang, L. Ren, F. Gao, F. Mu, Y. You, and Y. Liu, “Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China,” Clinical Rheumatology, vol. 30, no. 7, pp. 967–973, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Suleiman, D. Kamaliah, A. Nadeem, N. N. Naing, and C. H. Che Maraina, “Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus,” International Journal of Rheumatic Diseases, vol. 12, no. 2, pp. 100–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. V. D. Pradhan, M. M. Patwardhan, and K. Ghosh, “Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies,” Indian Journal of Dermatology, Venereology and Leprology, vol. 76, no. 2, pp. 145–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Julkunen, S. Ekblom-Kullberg, and A. Miettinen, “Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4,” Rheumatology International, vol. 32, no. 8, pp. 2445–2451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Žigon, K. Lakota, S. Čučnik et al., “Comparison and evaluation of different methodologies and tests for detection of antidsdna antibodies on 889 Slovenian patients ' and blood donors' sera,” Croatian Medical Journal, vol. 52, no. 6, pp. 694–702, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Akhter, R. W. Burlingame, A. L. Seaman, L. Magder, and M. Petri, “Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers,” Lupus, vol. 20, no. 12, pp. 1267–1274, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. B. A. Janssen, R. A. Luqmani, C. Gordon et al., “Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis,” British Journal of Rheumatology, vol. 33, no. 12, pp. 1112–1116, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. K. N. Lai, J. C. K. Leung, K. B. Lai, K. C. Wong, and C. K. W. Lai, “Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus,” Clinical Immunology and Immunopathology, vol. 81, no. 3, pp. 229–238, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. C. G. Moura, I. Lima, L. Barbosa et al., “Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus,” Journal of Clinical Laboratory Analysis, vol. 23, no. 1, pp. 19–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Trad, H. Ben Hassine, M. Khalifa et al., “Anti-C1q antibodies and systemic lupus erythematosus in the Tunisian population,” Pathologie Biologie, vol. 61, no. 3, pp. 113–116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Mahler, R. A. van Schaarenburg, and L. A. Trouw, “Anti-C1q autoantibodies, novel tests, and clinical consequences,” Frontiers in Immunology, vol. 4, article 117, 2013. View at Google Scholar
  31. D. M. Ricker, L. A. Hebert, R. Rohde, D. D. Sedmak, E. J. Lewis, and J. D. Clough, “Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels,” The American Journal of Kidney Diseases, vol. 18, no. 6, pp. 678–685, 1991. View at Publisher · View at Google Scholar · View at Scopus
  32. D. J. Birmingham, F. Irshaid, H. N. Nagaraja et al., “The complex nature of serum C3 and C4 as biomarkers of lupus renal flare,” Lupus, vol. 19, no. 11, pp. 1272–1280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. M. Shaldoum, Y. R. A. Mohammed, N. M. El Wakeel, and A. S. Gawish, “Evaluation of serum complement C3 and C4 leves as biomarkers for systemic lupus erythematosus,” The Egyptian Journal of Hospital Medicine, vol. 49, p. 16, 2012. View at Google Scholar